Search Results - "Boylan, Brian"

Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo by Zhi, Huiying, Rauova, Lubica, Hayes, Vincent, Gao, Cunji, Boylan, Brian, Newman, Debra K., McKenzie, Steven E., Cooley, Brian C., Poncz, Mortimer, Newman, Peter J.

“…The integrin family is composed of a series of 24 αβ heterodimer transmembrane adhesion receptors that mediate cell-cell and cell-extracellular matrix…”
Get full text

Tests of the Extension and Deadbolt Models of Integrin Activation by Zhu, Jieqing, Boylan, Brian, Luo, Bing-Hao, Newman, Peter J., Springer, Timothy A.

“…Despite extensive evidence that integrin conformational changes between bent and extended conformations regulate affinity for ligands, an alternative…”
Get full text

The proinflammatory phenotype of PECAM-1-deficient mice results in atherogenic diet-induced steatohepatitis by Goel, Reema, Boylan, Brian, Gruman, Lynn, Newman, Peter J, North, Paula E, Newman, Debra K

“…The severity of nonalcoholic steatohepatitis (NASH) is determined by environmental and genetic factors, the latter of which are incompletely characterized…”
Get more information

Inactivation of ompR Promotes Precocious Swarming and flhDC Expression in Xenorhabdus nematophila by Kim, Dong-jin, Boylan, Brian, George, Nicholas, Forst, Steven

“…Article Usage Stats Services JB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

The chromogenic Bethesda assay and the Nijmegen‐Bethesda assay for factor VIII inhibitors in hemophilia A patients: Are they equivalent? by Miller, Connie H., Boylan, Brian

Get full text

Evaluation of anti‐factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents by Boylan, Brian, Niemeyer, Glenn P., Werner, Bonnie, Miller, Connie H.

“…Introduction Bleeding episodes in patients who have haemophilia A (HA), a hereditary bleeding disorder caused by a deficiency in factor VIII (FVIII), are…”
Get full text

Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling by Gao, Cunji, Boylan, Brian, Fang, Juan, Wilcox, David A., Newman, Debra K., Newman, Peter J.

“…Unfractionated heparin (UFH) is a widely used anticoagulant that has long been known to potentiate platelet responses to subthreshold doses of platelet…”
Get full text

Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab by Miller, Connie H., Boylan, Brian, Payne, Amanda B., Driggers, Jennifer, Bean, Christopher J.

Get full text

Reagent substitution in the chromogenic Bethesda assay for factor VIII inhibitors by Payne, Amanda B., Miller, Connie H., Ellingsen, Dorothy, Driggers, Jennifer, Boylan, Brian, Bean, Christopher J.

Get full text

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens by Miller, Connie H, Ellingsen, Dorothy, Driggers, Jennifer, Boylan, Brian, Payne, Amanda B., Bethea, Fiona, Byams, Vanessa R, Soucie, J. Michael, Bean, Christopher J.

“…Background: The incidence and prevalence of inhibitors among hemophilia patients in the U.S. has not been determined. The Centers for Disease Control and…”
Get full text

Site-Specific Effects of PECAM-1 on Atherosclerosis in LDL Receptor–Deficient Mice by Goel, Reema, Schrank, Benjamin R, Arora, Shikha, Boylan, Brian, Fleming, Barbara, Miura, Hiroto, Newman, Peter J, Molthen, Robert C, Newman, Debra K

“…OBJECTIVE—Atherosclerosis is a vascular disease that involves lesion formation at sites of disturbed flow under the influence of genetic and environmental…”
Get full text

Comparison of clot‐based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study by Miller, C. H., Rice, A. S., Boylan, B., Shapiro, A. D., Lentz, S. R., Wicklund, B. M., Kelly, F. M., Soucie, J. M.

“…Summary Background Detection and validation of inhibitors (antibodies) to hemophilia treatment products are important for clinical care, evaluation of product…”
Get full text

Stability of specimens for use in the Centers for Disease Control and Prevention assays for factor VIII and IX inhibitors by Payne, Amanda B., Boylan, Brian, Niemeyer, Glenn, Werner, Bonnie, Driggers, Jennifer, Miller, Connie H., Bean, Christopher J.

“…Dear Editors, The Centers for Disease Control and Prevention (CDC) Nijmegen-Bethesda Assay (NBA) 1 is a modification of traditional methods 2,3 for measurement…”
Get full text

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors by Miller, C. H., Boylan, B., Shapiro, A. D., Lentz, S. R., Wicklund, B. M., Abshire, T. C., Dunn, A. L., Kempton, C. L., Soucie, J. M., Bethea, F., Payne, A., Bockenstedt, P. L., Brettler, D. B., Di Paola, J. A., Radhi, M., Neff, A. T., Tarantino, M. D., Manco‐Johnson, M. J., Knoll, C., Escobar, M. A., Eyster, M. E., Gill, J. C., Leissinger, C., Yaish, H.

“…Essentials Immunologic methods detect factor VIII (FVIII) antibodies in some inhibitor‐negative specimens. Specimens were tested by modified Nijmegen‐Bethesda…”
Get full text

Characterization of the anti‐factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence‐based immunoassay by Boylan, B., Rice, A. S., Dunn, A. L., Tarantino, M. D., Brettler, D. B., Barrett, J. C., Miller, C. H., Abshire, T. C., Kempton, C. L., Bockenstedt, P. L., Di Paola, J. A., Radhi, M., Lentz, S. R., Massey, G., Neff, A. T., Shapiro, A. D., Wicklund, B. M., Manco‐Johnson, M. J., Knoll, C., Escobar, M. A., Elaine Eyster, M., Gill, J. C., Leissinger, C., Yaish, H.

“…Summary Background The development of neutralizing antibodies, referred to as inhibitors, against factor VIII is a major complication associated with FVIII…”
Get full text

Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain by Gao, Cunji, Boylan, Brian, Bougie, Dan, Gill, Joan C, Birenbaum, Jessica, Newman, Debra K, Aster, Richard H, Newman, Peter J

“…Thrombocytopenia and thrombosis following treatment with the integrin αIIbβ3 antagonist eptifibatide are rare complications caused by patient antibodies…”
Get full text

Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia by Bougie, Daniel W., Nayak, Dhirendra, Boylan, Brian, Newman, Peter J., Aster, Richard H.

“…Drug-induced immune thrombocytopenia (DITP) is a relatively common and sometimes life-threatening condition caused by antibodies that bind avidly to platelets…”
Get full text

Survey of the anti–factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence‐based immunoassay by Boylan, B., Rice, A. S., Neff, A. T., Manco‐Johnson, M. J., Kempton, C. L., Miller, C. H., Abshire, T. C., Dunn, A., Bockenstedt, P. L., Brettler, D. B., Di Paola, J. A., Radhi, M., Lentz, S. R., Massey, G., Barrett, J. C., Shapiro, A. D., Tarantino, M., Wicklund, B. M., Knoll, C., Escobar, M. A., Eyster, M. E., Gill, J. C., Leissinger, C., Yaish, H.

“…Essentials Studies characterizing neutralizing antibodies (inhibitors) in hemophilia B (HB) are lacking. The current study describes anti–factor (F) IX…”
Get full text

Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti–human platelet agents by Boylan, Brian, Berndt, Michael C., Kahn, Mark L., Newman, Peter J.

“…GPVI is a 62-kDa membrane glycoprotein expressed in noncovalent association with the Fc receptor γ chain on human and murine platelets and serves as the major…”
Get full text

Anti-GPVI–associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface by Boylan, Brian, Chen, Hong, Rathore, Vipul, Paddock, Cathy, Salacz, Michael, Friedman, Kenneth D., Curtis, Brian R., Stapleton, Michelle, Newman, Debra K., Kahn, Mark L., Newman, Peter J.

“…Platelet glycoprotein (GP) VI is a 62-kDa membrane glycoprotein that exists on both human and murine platelets in a noncovalent complex with the Fc receptor…”
Get full text